Dose‐specific clinical outcomes in patients with opioid use disorder treated with 24–32 mg/day of buprenorphine

Documents similaires

• Commentary on Gregory et al .: Fear of precipitated opioid withdrawal should not prevent buprenorphine initiation
  par: Sandra A. Springer
  Publié: (2024)
• A comparative study of treatment retention in opioid use disorder: Subcutaneous injectable versus sublingual buprenorphine
  par: Charles Deng, et autres
  Publié: (2025)
• Pharmacological treatment strategies to manage precipitated withdrawal following the administration of buprenorphine in opioid use disorder: A systematic review
  par: Emmert Roberts, et autres
  Publié: (2026)
• Patient outcomes following buprenorphine treatment for opioid use disorder: A retrospective analysis of the influence of patient‐ and prescriber‐level characteristics in Massachusetts, USA
  par: Gary J. Young, et autres
  Publié: (2024)
• Commentary on D'Agata Mount et al.: Higher dose buprenorphine to improve retention in opioid use disorder treatment, prevent relapse, and optimize integrated care interventions
  par: Paolo Mannelli
  Publié: (2024)